Katherine Ann Devitt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Katherine Ann Devitt has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Juli-Anne Gardner
Department of Pathology and Laboratory Medicine, University of Vermont Medical Center, Burlington, VT, USA
4 shared publicationsWolfgang Kern
MLL Munich Leukemia Laboratory Munich Germany
3 shared publicationsAndrea Illingworth
Department of Flow Cytometry Dahl‐Chase Diagnostic Services/Versant Diagnostics Bangor Maine USA
2 shared publicationsBritni R. E. Bryant
Department of Pathology and Laboratory Medicine, University of Vermont Medical Center, Burlington, VT, USA
2 shared publicationsAhmad Al‐Attar
Department of Pathology University of Pittsburgh Pennsylvania USA
1 shared publicationAllyson J. Wong
Pathology and Laboratory Medicine Lahey Hospital and Medical Center Burlington Massachusetts USA
1 shared publication
Latest Publications
- Open Access
- 22 October 2025
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 108 (6) , 430-447
A practical approach to panel design, validation, and interpretation for the evaluation of T ‐cell neoplasms by flow cytometry
The diagnosis of T‐cell neoplasms remains one of the most challenging areas in hematopathology due to the immunophenotypic heterogeneity and subtle aberrancies often present in these entities. This “Best Practice” manuscript provides a practical framework for laboratories to design, validate, and interpret immunophenotyping studies of immature and mature T‐cell neoplasms. We outline the utility of key antigens in the screening and classification of T‐cell lymphomas/leukemia including TRBC1 and TRBC2. Analytical strategies using the “difference from normal” method and template‐based gating are discussed, along with validation considerations aligned with CLSI H62 guidelines. By integrating these principles into laboratory workflows, this manuscript aims to standardize and improve the assessment of T‐cell neoplasms across diverse clinical settings.
- 22 October 2025
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 108 (6) , 430-447
Open AccessA practical approach to panel design, validation, and interpretation for the evaluation of T ‐cell neoplasms by flow cytometry
The diagnosis of T‐cell neoplasms remains one of the most challenging areas in hematopathology due to the immunophenotypic heterogeneity and subtle aberrancies often present in these entities. This “Best Practice” manuscript provides a practical framework for laboratories to design, validate, and interpret immunophenotyping studies of immature and mature T‐cell neoplasms. We outline the utility of key antigens in the screening and classification of T‐cell lymphomas/leukemia including TRBC1 and TRBC2. Analytical strategies using the “difference from normal” method and template‐based gating are discussed, along with validation considerations aligned with CLSI H62 guidelines. By integrating these principles into laboratory workflows, this manuscript aims to standardize and improve the assessment of T‐cell neoplasms across diverse clinical settings.
- Open Access
- 20 July 2024
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 108 (1) , 77-85
Implementation of flow cytometry testing on rare matrix samples: Special considerations and best practices when the sample is unique or difficult to obtain
The publication of Clinical and Laboratory Standards Institute's guideline H62 has provided the flow cytometry community with much‐needed guidance on development and validation of flow cytometric assays (CLSI, 2021). It has also paved the way for additional exploration of certain topics requiring additional guidance. Flow cytometric analysis of rare matrices, or unique and/or less frequently encountered specimen types, is one such topic and is the focus of this manuscript. This document is the result of a collaboration subject matter experts from a diverse range of backgrounds and seeks to provide best practice consensus guidance regarding these types of specimens. Herein, we define rare matrix samples in the setting of flow cytometric analysis, address validation implications and challenges with these samples, and describe important considerations of using these samples in both clinical and research settings.
- 20 July 2024
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 108 (1) , 77-85
Open AccessImplementation of flow cytometry testing on rare matrix samples: Special considerations and best practices when the sample is unique or difficult to obtain
The publication of Clinical and Laboratory Standards Institute's guideline H62 has provided the flow cytometry community with much‐needed guidance on development and validation of flow cytometric assays (CLSI, 2021). It has also paved the way for additional exploration of certain topics requiring additional guidance. Flow cytometric analysis of rare matrices, or unique and/or less frequently encountered specimen types, is one such topic and is the focus of this manuscript. This document is the result of a collaboration subject matter experts from a diverse range of backgrounds and seeks to provide best practice consensus guidance regarding these types of specimens. Herein, we define rare matrix samples in the setting of flow cytometric analysis, address validation implications and challenges with these samples, and describe important considerations of using these samples in both clinical and research settings.
- Open Access
- 3 May 2024
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 106 (3) , 192-202
TRBC1 in flow cytometry: Assay development, validation, and reporting considerations
The assessment of T‐cell clonality by flow cytometry has long been suboptimal, relying on aberrant marker expression and/or intensity. The introduction of TRBC1 shows much promise for improving the diagnosis of T‐cell neoplasms in the clinical flow laboratory. Most laboratories considering this marker already have existing panels designed for T‐cell workups and will be determining how best to incorporate TRBC1. We present this comprehensive summary of TRBC1 and supplemental case examples to familiarize the flow cytometry community with its potential for routine application, provide examples of how to incorporate it into T‐cell panels, and signal caution in interpreting the results in certain diagnostic scenarios where appropriate.
- 3 May 2024
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 106 (3) , 192-202
Open AccessTRBC1 in flow cytometry: Assay development, validation, and reporting considerations
The assessment of T‐cell clonality by flow cytometry has long been suboptimal, relying on aberrant marker expression and/or intensity. The introduction of TRBC1 shows much promise for improving the diagnosis of T‐cell neoplasms in the clinical flow laboratory. Most laboratories considering this marker already have existing panels designed for T‐cell workups and will be determining how best to incorporate TRBC1. We present this comprehensive summary of TRBC1 and supplemental case examples to familiarize the flow cytometry community with its potential for routine application, provide examples of how to incorporate it into T‐cell panels, and signal caution in interpreting the results in certain diagnostic scenarios where appropriate.
- Open Access
- 1 January 2021
- Published by Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais in Autopsy Case Reports
- Vol. 11
Mantle cell lymphoma presenting with lethal atraumatic splenic rupture
Autops Case Rep, vol.11, e2021340, 2021
- 1 January 2021
- Published by Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais in Autopsy Case Reports
- Vol. 11
Open AccessMantle cell lymphoma presenting with lethal atraumatic splenic rupture
Autops Case Rep, vol.11, e2021340, 2021
- Open Access
- 1 January 2020
- Published by Elsevier in Academic Pathology
- Vol. 7
Educational Case: Cytogenetics
- 1 January 2020
- Published by Elsevier in Academic Pathology
- Vol. 7
Open AccessEducational Case: Cytogenetics
- Open Access
- 1 January 2019
- Published by Elsevier in Academic Pathology
- Vol. 6
Educational Case: Chronic Myeloid Leukemia
- 1 January 2019
- Published by Elsevier in Academic Pathology
- Vol. 6
Open AccessEducational Case: Chronic Myeloid Leukemia
- Open Access
- 1 January 2019
- Published by Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais in Autopsy Case Reports
- Vol. 9 (3) , e2019090
High-grade B-Cell lymphoma with MYC and BCL6 rearrangements associated with Richter transformation of chronic lymphocytic leukemia
Richter transformation (RT), or Richter syndrome, is defined as the transformation of chronic lymphocytic leukemia (CLL) to an aggressive B-cell lymphoma. The vast majority, up to 99%, transform into diffuse large B-cell lymphoma (DLBCL), with a small subset (<1%) becoming classical Hodgkin lymphoma. Approximately half of RT cases progress through a pathway involving dysregulation of C-MYC. High-grade B-cell lymphoma (HGBL) is a recent diagnostic category of aggressive B-cell lymphomas set forth in the updated 2017 WHO Classification of Hematopoietic and Lymphoid Tissues. HGBL with MYC and BCL2 and/or BCL6 rearrangements, formerly "double-hit" and "triple-hit" lymphomas, comprise the majority of HGBL cases. Patients with HGBL have a worse prognosis than those with diffuse large B-cell lymphoma. We present a case of RT with rearrangements of MYC and BCL6. To our knowledge, there are no reported cases of RT with a "double-hit" lymphoma genotype.
- 1 January 2019
- Published by Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais in Autopsy Case Reports
- Vol. 9 (3) , e2019090
Open AccessHigh-grade B-Cell lymphoma with MYC and BCL6 rearrangements associated with Richter transformation of chronic lymphocytic leukemia
Richter transformation (RT), or Richter syndrome, is defined as the transformation of chronic lymphocytic leukemia (CLL) to an aggressive B-cell lymphoma. The vast majority, up to 99%, transform into diffuse large B-cell lymphoma (DLBCL), with a small subset (<1%) becoming classical Hodgkin lymphoma. Approximately half of RT cases progress through a pathway involving dysregulation of C-MYC. High-grade B-cell lymphoma (HGBL) is a recent diagnostic category of aggressive B-cell lymphomas set forth in the updated 2017 WHO Classification of Hematopoietic and Lymphoid Tissues. HGBL with MYC and BCL2 and/or BCL6 rearrangements, formerly "double-hit" and "triple-hit" lymphomas, comprise the majority of HGBL cases. Patients with HGBL have a worse prognosis than those with diffuse large B-cell lymphoma. We present a case of RT with rearrangements of MYC and BCL6. To our knowledge, there are no reported cases of RT with a "double-hit" lymphoma genotype.
- Open Access
- 1 January 2018
- Published by Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais in Autopsy Case Reports
- Vol. 8 (4) , e2018055
Intravascular large B-cell lymphoma: The Great Imitator
Autops Case Rep, vol.8, n4, e2018055, 2018
- 1 January 2018
- Published by Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais in Autopsy Case Reports
- Vol. 8 (4) , e2018055
Open AccessIntravascular large B-cell lymphoma: The Great Imitator
Autops Case Rep, vol.8, n4, e2018055, 2018